A simultaneous or sequential combination of brentuximab vedotin and radiotherapy is feasible and well tolerated in patients ...

Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of T-cell malignancies that manifest primarily in the skin. By far the most common variant of CTCL is mycosis fungoides and its ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with ...

Clinical trial findings showed an objective response rate of 36.2%, with 8.7% of patients having a complete response. The Food and Drug Administration (FDA) has approved Lymphir (denileukin ...

Relapsed or refractory cutaneous t-cell lymphoma can be treated in adults with the new FDA approval of denileukin diftitox immunotherapy. The FDA announced their approval of deileukin diftitox-cxdl ...

A nurse practitioner asks for an opinion regarding a skin lesion on a 39-year-old African American man. The lesion is located on the inner left thigh and is mildly pruritic. It measures an irregular ...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life ...

Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval ...